Cost-effectiveness analysis of a randomized plus observational cohort trial.
Analyze cost-effectiveness of Spine Patient Outcomes Research Trial data over 4 years comparing surgery with nonoperative care for three common diagnoses: spinal stenosis (SPS), degenerative spondylolisthesis (DS), and intervertebral disc herniation (IDH).
Spine surgery rates continue to rise in the United States, but the safety and economic value of these procedures remain uncertain.
Patients with image-confirmed diagnoses were followed in randomized or observational cohorts with data on resource use, productivity, and EuroQol EQ-5D health state values measured at 6 weeks, 3, 6, 12, 24, 36, and 48 months. For each diagnosis, cost per quality-adjusted life year (QALY) gained in 2004 US dollars was estimated for surgery relative to nonoperative care using a societal perspective, with costs and QALYs discounted at 3% per year.
Surgery was performed initially or during the 4-year follow-up among 414 of 634 (65.3%) SPS, 391 of 601 (65.1%) DS, and 789 of 1192 (66.2%) IDH patients. Surgery improved health, with persistent QALY differences observed through 4 years (SPS QALY gain 0.22; 95% confidence interval, CI: 0.15, 0.34; DS QALY gain 0.34, 95% CI: 0.30, 0.47; and IDH QALY gain 0.34, 95% CI: 0.31, 0.38). Costs per QALY gained decreased for SPS from $77,600 at 2 years to $59,400 (95% CI: $37,059, $125,162) at 4 years, for DS from $115,600 to $64,300 per QALY (95% CI: $32,864, $83,117), and for IDH from $34,355 to $20,600 per QALY (95% CI: $4,539, $33,088).
Comparative effectiveness evidence for clearly defined diagnostic groups from Spine Patient Outcomes Research Trial shows good value for surgery compared with nonoperative care over 4 years.
Spine Patient Outcomes Research Trial data over 4 years comparing surgery with nonoperative care for three common diagnoses—spinal stenosis, degenerative spondylolisthesis, and intervertebral disc herniation—are presented. The value of surgery for these conditions improved when considered over 4 years compared with 2-year cost-effectiveness results.
*The Dartmouth Institute for Health Policy and Clinical Practice, Dartmouth Medical School, Lebanon, NH
†William Beaumont Hospital, Royal Oak, MI
‡Rush University Medical Center, Chicago, IL
§Rothman Institute at Thomas Jefferson University, Philadelphia, PA
¶Washington University School of Medicine, St. Louis, MO
[BULLET OPERATOR]Harvard School of Public Health, Boston, MA.
Address correspondence and reprint requests to Anna N. A. Tosteson, ScD, The Dartmouth Institute for Health Policy, & Clinical Practice, Clinical Research HB7505, One Medical Center Drive, Lebanon, NH 03756; E-mail: firstname.lastname@example.org.
Acknowledgment date: December 7, 2010. Acceptance date: August 10, 2011.
The manuscript submitted does not contain information about medical device(s)/drug(s).
Grant funds were received in support of this work. One or more of the author(s) has/have received or will receive benefits for personal or professional use from a commercial party related directly or indirectly to the subject of this manuscript: e.g., honoraria, gifts, consultancies, royalties, stocks, stock options, decision-making position.